- Home
- NDLS vs DARE Comparison
NDLS vs DARE Comparison
Compare NDLS & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- DARE
- Stock Information
- Founded
- NDLS 1995
- DARE 2015
- Country
- NDLS United States
- DARE United States
- Employees
- NDLS N/A
- DARE N/A
- Industry
- NDLS Restaurants
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- DARE Health Care
- Exchange
- NDLS Nasdaq
- DARE Nasdaq
- Market Cap
- NDLS 33.2M
- DARE 28.0M
- IPO Year
- NDLS 2013
- DARE N/A
- Fundamental
- Price
- NDLS $0.67
- DARE $2.03
- Analyst Decision
- NDLS Buy
- DARE Strong Buy
- Analyst Count
- NDLS 2
- DARE 2
- Target Price
- NDLS $3.00
- DARE $10.00
- AVG Volume (30 Days)
- NDLS 170.0K
- DARE 123.1K
- Earning Date
- NDLS 11-05-2025
- DARE 11-13-2025
- Dividend Yield
- NDLS N/A
- DARE N/A
- EPS Growth
- NDLS N/A
- DARE N/A
- EPS
- NDLS N/A
- DARE N/A
- Revenue
- NDLS $494,752,000.00
- DARE N/A
- Revenue This Year
- NDLS $1.19
- DARE $6,864.02
- Revenue Next Year
- NDLS N/A
- DARE $4,922.46
- P/E Ratio
- NDLS N/A
- DARE N/A
- Revenue Growth
- NDLS N/A
- DARE N/A
- 52 Week Low
- NDLS $0.55
- DARE $1.83
- 52 Week High
- NDLS $1.74
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- NDLS 40.55
- DARE 39.93
- Support Level
- NDLS $0.66
- DARE $2.05
- Resistance Level
- NDLS $0.76
- DARE $2.15
- Average True Range (ATR)
- NDLS 0.03
- DARE 0.07
- MACD
- NDLS 0.00
- DARE 0.02
- Stochastic Oscillator
- NDLS 18.18
- DARE 15.54
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.